Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice

Xiaoyan Li; Steve Deitelzweig; Allison Keshishian; Melissa Hamilton; Ruslan Horblyuk; Kiran Gupta; Xuemei Luo; Jack Mardekian; Keith Friend; Anagha Nadkarni; Xianying Pan; Gregory Y. H. Lip

doi:10.1160/TH17-01-0068

Thrombosis and Haemostasis, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Thromb Haemost 2017; 117(06): 1072-1082
DOI: 10.1160/TH17-01-0068

Coagulation and Fibrinolysis

Schattauer GmbH

Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice

A propensity-matched analysis of 76,940 patients

Authors

Xiaoyan Li

¹Bristol-Myers Squibb Company, Lawrenceville, New Jersey, USA
Steve Deitelzweig

²Ochsner Clinic Foundation, Department of Hospital Medicine, New Orleans, Louisianna, USA and The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, Louisianna, USA
Allison Keshishian

³STATinMED Research, Ann Arbor, Michigan, USA
Melissa Hamilton

¹Bristol-Myers Squibb Company, Lawrenceville, New Jersey, USA
Ruslan Horblyuk

⁴Pfizer, Inc., New York, New York, USA
Kiran Gupta

¹Bristol-Myers Squibb Company, Lawrenceville, New Jersey, USA
Xuemei Luo

⁵Pfizer, Inc., Groton, Conneticut, USA
Jack Mardekian

⁴Pfizer, Inc., New York, New York, USA
Keith Friend

¹Bristol-Myers Squibb Company, Lawrenceville, New Jersey, USA
Anagha Nadkarni

¹Bristol-Myers Squibb Company, Lawrenceville, New Jersey, USA
Xianying Pan

⁶Bristol-Myers Squibb Company, Wallingford, Conneticut, USA
Gregory Y. H. Lip

⁷Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK

⁸Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

Abstract

Summary

The ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major bleeding in non-valvular atrial fibrillation (NVAF) patients treated with apixaban compared to warfarin. This retrospective study used four large US claims databases (MarketScan, PharMetrics, Optum, and Humana) of NVAF patients newly initiating apixaban or warfarin from January 1, 2013 to September 30, 2015. After 1:1 warfarin-apixaban propensity score matching (PSM) within each database, the resulting patient records were pooled. Kaplan-Meier curves and Cox proportional hazards models were used to estimate the cumulative incidence and hazard ratios (HRs) of stroke/SE and major bleeding (identified using the first listed diagnosis of inpatient claims) within one year of therapy initiation. The study included a total of 76,940 (38,470 warfarin and 38,470 apixaban) patients. Among the 38,470 matched pairs, 14,563 were from MarketScan, 7,683 were from PharMetrics, 7,894 were from Optum, and 8,330 were from Humana. Baseline characteristics were balanced between the two cohorts with a mean (standard deviation [SD]) age of 71 (12) years and a mean (SD) CHA₂DS₂-VASc score of 3.2 (1.7). Apixaban initiators had a significantly lower risk of stroke/SE (HR: 0.67, 95 % CI: 0.59–0.76) and major bleeding (HR: 0.60, 95 % CI: 0.54–0.65) than warfarin initiators. Different types of stroke/SE and major bleeding – including ischaemic stroke, haemorrhagic stroke, SE, intracranial haemorrhage, gastrointestinal bleeding, and other major bleeding – were all significantly lower for apixaban compared to warfarin treatment. Subgroup analyses (apixaban dosage, age strata, CHA₂DS₂-VASc or HAS-BLED score strata, or dataset source) all show consistently lower risks of stroke/SE and major bleeding associated with apixaban as compared to warfarin treatment. This is the largest “real-world” study on apixaban effectiveness and safety to date, showing that apixaban initiation was associated with significant risk reductions in stroke/SE and major bleeding compared to warfarin initiation after PSM. These benefits were consistent across various high-risk subgroups and both the standard-and low-dose apixaban dose regimens.

Note: The review process for this manuscript was fully handled by Christian Weber, Editor in Chief.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Apixaban - warfarin - non-valvular atrial fibrillation - stroke - major bleeding

Volltext

Referenzen

References
1 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-988.
2 Colilla S, Crow A, Petkun W. et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U. S. adult population. Am J Cardiol 2013; 112: 1142-1147.
3 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
4 Sam C, Massaro JM, D’Agostino Sr RB. et al. Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framing-ham Heart Study). Am J Cardiol 2004; 94: 947-951.
5 January CT, Wann LS, Alpert JS. et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130: e199-e267.
6 Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011; 31: 326-343.
7 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
8 Patel MR, Mahaffey KW, Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
9 Granger CB, Alexander JH, McMurray JJ. et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med. 2011; 365: 981-992.
10 Giugliano RP, Ruff CT, Braunwald E. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104.
11 Bristol-Meyers Squibb Company and Pfizer Inc.. Eliquis (apixaban) U. S. Full Prescribing Information. Available at http://packageinserts.bms.com/pi/pi_eliquis.pdf Accessed January 29, 2017.
12 Hansen LG, Chang S. Health research data for the real world: the Marketscan databases. Available at truvenhealth.com/portals/0/assets/PH_11238_0612_TEMP_MarketScan_WP_FINAL.pdf Published July 2011; Accessed January 26, 2017.
13 IMS Health. PharMetrics Plus Data Dictionary. Available at tri.uams.edu/files/2015/08/Pharmetrics-Plus-Data-Dictionary-Jan-2013.pdf Accessed January 26, 2017.
14 Optum. Clinformatics Data Mart. Available at https://www.optum.com/content/dam/optum/resources/productSheets/Clinformatics_for_Data_Mart.pdf Published 2014; Accessed January 26, 2016.
15 Michels SL, Uribe C. The Humana database – a data source for pharmacoepidemiologic research. [Presentation] 28th Annual International Conference for Pharmacoepidemiology and Therapeutic Risk Management. Barcelona, Spain: 23rd-26th August 2012.
16 Pelton SI, Weycker D, Farkouh RA. et al. Risk of pneumococcal disease in children with chronic medical conditions in the era of pneumococcal conjugate vaccine. Clin Infect Dis 2014; 59: 615-623.
17 Weycker D, Li X, Barron R. et al. Importance of risk factors for febrile neutropenia among patients receiving chemotherapy regimens not classified as high-risk in guidelines for myeloid growth factor use. J Natl Compr Canc Netw 2015; 13: 979-986.
18 Sun P, Kohrman M, Liu J. et al. Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis. Curr Med Res Opin 2012; 28: 657-663.
19 Guérin A, Sasane M, Zhang J. et al. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden. J Med Econ 2015; 18: 312-322.
20 Seeger JD, Bykov K, Bartels DB. et al. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost 2015; 114: 1277-1289.
21 Broder MS, Neary MP, Chang E. et al. Treatments, complications, and health-care utilization associated with acromegaly: a study in two large United States databases. Pituitary 2014; 17: 333-341.
22 Jensen PN, Johnson K, Floyd J. et al. Identifying atrial fibrillation from electronic medical data: a systematic review. Pharmacoepidemiol Drug Saf 2012; 21: 141-147.
23 Thigpen JL, Dillon C, Forster KB. et al. Validity of international classification of disease codes to identify ischaemic stroke and intracranial hemorrhage among individuals with associated diagnosis of atrial fibrillation. Circ Cardiovasc Qual Outcomes 2015; 8: 8-14.
24 Cunningham A, Stein CM, Chung CP. et al. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf 2011; 20: 560-566.
25 Pan X, Kachroo S, Liu X. et al. Real world discontinuation among early users of apixaban, dabigatran, rivaroxaban or warfarin among atrial fibrillation patients newly initiated on anticoagulation therapy: tell of first 200 days. Eur Heart J 2014; 35: 897.
26 Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 2014; 33: 1242-1258.
27 Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009; 28: 3083-3107.
28 Halvorsen S, Atar D, Yang H. et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 2014; 35: 1864-1872.
29 Lopes RD, Al-Khatib SM, Wallentin L. et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet 2012; 380: 1749-1758.
30 Yao X, Abraham NS, Sangaralingham LR. et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc 2016; 5: e003725.
31 Lip GY, Keshishian A, Kamble S. et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. Thromb Haemost 2016; 116: 975-986.
32 Freedman B, Lip GY. “Unreal world” or “real world” data in oral anticoagulant treatment of atrial fibrillation. Thromb Haemost 2016; 116: 587-589.

Zusatzmaterial

Online Zusatzmaterial (PDF) (PDF)